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Abstract
Introduction: Atrial fibrillation is an independent risk factor of thromboembolism. Women with atrial fibrillation are at
a higher overall risk for stroke compared to men with atrial fibrillation. The aim of this study was to evaluate for sex
differences in patients with acute stroke and atrial fibrillation, regarding risk factors, treatments received and outcomes.
Methods: Data were analyzed from the ‘‘Recurrence and Cerebral Bleeding in Patients with Acute Ischemic Stroke and
Atrial Fibrillation’’ (RAF-study), a prospective, multicenter, international study including only patients with acute stroke
and atrial fibrillation. Patients were followed up for 90 days. Disability was measured by the modified Rankin Scale (0–2
favorable outcome, 3–6 unfavorable outcome).
Results: Of the 1029 patients enrolled, 561 were women (54.5%) (p< 0.001) and younger (p< 0.001) compared to
men. In patients with known atrial fibrillation, women were less likely to receive oral anticoagulants before index stroke
(p¼ 0.026) and were less likely to receive anticoagulants after stroke (71.3% versus 78.4%, p¼ 0.01). There was no
observed sex difference regarding the time of starting anticoagulant therapy between the two groups (6.4 11.7 days for
men versus 6.5 12.4 days for women, p¼ 0.902). Men presented with more severe strokes at onset (mean NIHSS
9.2 6.9 versus 8.1 7.5, p< 0.001). Within 90 days, 46 (8.2%) recurrent ischemic events (stroke/TIA/systemic embol-
ism) and 19 (3.4%) symptomatic cerebral bleedings were found in women compared to 30 (6.4%) and 18 (3.8%) in men
(p¼ 0.28 and p¼ 0.74). At 90 days, 57.7% of women were disabled or deceased, compared to 41.1% of the men
(p< 0.001). Multivariate analysis did not confirm this significance.
Conclusions: Women with atrial fibrillation were less likely to receive oral anticoagulants prior to and after stroke
compared to men with atrial fibrillation, and when stroke occurred, regardless of the fact that in our study women were
younger and with less severe stroke, outcomes did not differ between the sexes.
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Introduction
Strokes in atrial fibrillation (AF) patients are common
and frequently devastating (70–80% of patients die or
become disabled,1,2 yet these strokes are preventable
with anticoagulant therapy: 64% reduction in the risk
of stroke and 25% reduction in mortality.3
Recent evidence shows that women are more fre-
quently affected by AF compared to men, and have a
higher associated risk for thromboembolic events.4–6
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Therefore, female sex has been added as an independ-
ent risk-factor when calculating the CHA2DS2-VASc-
score.7 Despite of this increased risk, women with AF
still tend to be less treated with anticoagulants.8,9
The ‘‘Early Recurrence and Cerebral Bleeding in
Patients with Acute Ischemic Stroke and Atrial
Fibrillation’’ (RAF) Study investigated for (1) the risk
of recurrent ischemic event and severe bleeding; (2) the
risk factors for recurrence and bleeding; and (3) the risks
of recurrence and bleeding associated with anticoagulant
therapy and its starting time after the acute stroke.10 The
results of this study have been recently published.10
The aim of this study was to evaluate the sex-
differences in patients with acute stroke and AF, regard-
ing risk factors, treatments received and outcomes.
Methods
The methods and results of the RAF-study have been
published recently.10 Briefly, RAF-study was per-
formed between January 2012 and March 2014 and
included 29 Stroke Units across Europe and Asia. All
of the participating 29 Stroke Units provided standard
stroke unit care and monitoring.10
On admission, stroke severity was assessed using
the National Institutes of Health Stroke Scale
(NIHSS). All patients underwent cerebral computed
tomography examination without contrast or cerebral
magnetic resonance to exclude intracranial hemor-
rhage. Thrombolysis treatment was administered as
per local standard protocol, when appropriate. All
patients were monitored for blood pressure, tempera-
ture, glucose level, heart rate, and blood gases in the
first days after stroke. The choice of anticoagulant
treatment (low molecular weight heparin [LMWH]
or oral anticoagulants), as well as the day of its initi-
ation, was left to the discretion of the treating phys-
icians. AF was classified as paroxysmal, persistent, or
permanent. A second brain computed tomography
scan or magnetic resonance was performed 24–72 h
from stroke onset in all patients. Hemorrhagic trans-
formation was defined as any degree of hyperdensity
within the area of low attenuation and was classified
as either hemorrhagic infarction or parenchymal
hematoma.11,12 The sites and sizes of the qualifying
infarcts were determined based on standard templates
as small, medium, large anterior or large posterior
infarctions.11,13,14 Data on known stroke risk factors
and treatment were collected and reported in the main
paper.10 The CHA2DS2-VASc score before the index
event was also calculated. The standard protocol also
included a transthoracic echocardiography (TTE)
during the hospital stay. Patients were followed up
prospectively through face-to-face or telephone inter-
views. Study outcomes were (1) recurrent ischemic
cerebrovascular events (stroke or TIA) and symptom-
atic systemic embolism; (2) symptomatic cerebral
bleedings and major extracerebral bleeding at 90
days. The primary outcome was the composite of
stroke, TIA, symptomatic systemic embolism, symp-
tomatic cerebral bleeding, and major extracerebral
bleeding. Disability and mortality at 90 days were
also assessed using the modified Rankin Scale
(mRS). Functional outcome was defined as either
favorable (mRS 0–2) or unfavorable (mRS 3–6).
Statistical analysis
Continuous variables, as well as NIHSS score, were
reported as mean SD, and categorical variables
were reported as percentages. Pearson’s chi-square
test was used to compare categorized proportions. A
comparison of discrete variables was conducted using
a non-parametric test (Mann–Whitney). Multivariate
logistic regression was performed in order to investi-
gate sex differences for dichotomous outcomes.
Included variables were: age, vascular risk factors,
NIHSS on admission, the type of AF, lesion size,
antithrombotic treatment before and after stroke, pre-
vious use of statins. The decision concerning which
variables to include and to adjust in the multivariable
analysis was guided by either the presence of an a
priori theoretical or biological relationship among
the examined patient characteristics as well as pri-
mary endpoints.15 A two-sided p< 0.05 was con-
sidered significant for all statistical tests. All
statistical analyses were performed using software
SPSS/PC Win package 20.0.
Results
Overall, 1037 consecutive patients were enrolled in the
study (59 from Asia) and 1029 were included in the
analysis (eight excluded for incomplete data). Overall,
561 women were included (54.5%, p< 0.001), and they
were on average younger (p< 0.001) compared to men.
There was no observed difference in AF subtypes (par-
oxysmal, persistent or permanent) between the sexes
(Table 1). History of myocardial infarction was more
common in men (p¼ 0.002), as was history of periph-
eral arterial disease (p¼ 0.003) and aortic atheroscler-
osis (p¼ 0.016). Also, men more often had a
pacemaker (p¼ 0.023) and were more often taking
statins at the time of stroke onset (p< 0.001), while
smoking and alcohol abuse were more common in
men (p< 0.001). Previous use of antiplatelet agents
was not significantly different between the two
groups, while the use of anticoagulants was less fre-
quent in women (25.5% versus 31.9%, respectively,
p¼ 0.026).
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Both large anterior lesions (p¼ 0.012) and leukoar-
aiosis (p< 0.001) were more frequent in women
(Table 1). On transthoracic echocardiography, per-
formed on 853 patients, mitral disease, aortic disease
and severe atrial enlargement were more frequent in
women (p¼ 0.025, p¼ 0.03 and p¼ 0.007, respectively),
while cardiomyopathy was more frequent in men
(p¼ 0.001). Tricuspid disease, and presence of aortic
or mitral prostheses were not significantly different
between the sexes (p¼ ns) (Table 2).
Types of revascularization therapy administered
after ischemic stroke did not differ between the two
groups. Anticoagulants were less often prescribed in
women than in men after index stroke (71.3% versus
78.4%, respectively, p¼ 0.01). There were no sex differ-
ences regarding the time of initiating anticoagulant
therapy between the two groups: (6.4 11.7 days for
men versus 6.5 12.4 days for women, p¼ 0.902)
(Table 3). A CHA2DS2-VASc score of 3 was found in
5.7% and 27.8% for women and men, respectively
Table 1. Baseline characteristics of patients.
Variables Women Men p-Value
Age (years) (mean SD) 75.1 9.04 77.2 9.73 <0.001
Type of AF, n (%):
Paroxysmal 198 (35.4) 166 (35.6) 0.948
Permanent 248 (44.4) 224 (48.1) 0.232
Persistent 115 (20.2) 76 (16.3) 0.091
Concomitant medical history, n (%):
Hypertension 457 (82.3) 364 (78.3) 0.113
Hyperlipidemia 161 (29.2) 171 (36.9) 0.011
Diabetes mellitus 144 (25.9) 120 (25.8) 1.0
History of stroke/TIA 138 (25.0) 127 (27.4) 0.39
Chronic heart failure 99 (17.7) 94 (20.2) 0.336
History of myocardial infarction 72 (13.0) 94 (20.2) 0.002
History of peripheral artery disease 36 (6.49) 56 (12.1) 0.003
Aortic atherosclerosis 44 (7.86) 58 (12.5) 0.016
Atherosclerosis in other sitesa 115 (21.3) 116 (25.2) 0.153
Pacemaker 36 (6.45) 49 (10.5) 0.023
Smoking 67 (12.1) 197(42.4) <0.001
Alcoholism 7 (1.25) 61 (13.1) <0.001
Previous use of oral anticoagulants, n (%): 141 (25.5) 148 (31.9) 0.026
Previous use of antiplatelets, n (%) 248 (44.8) 217 (46.9) 0.528
Previous use of statins, n (%) 115 (20.8) 145 (31.2) <0.001
Lesion site and size, n (%):
Small lesion 187 (33.4) 192 (41.1) 0.011
Medium lesion 202 (36.1) 166 (35.5) 0.896
Large anterior lesion 137 (24.5) 83 (17.8) 0.012
Large posterior lesion 34 (6.1) 25 (5.4) 0.687
Leukoaraiosis, n (%) 261 (47.1) 165 (35.9) <0.001
NIHSS, mean SD 8.1 7.5 9.2 6.9 <0.001
Systolic AP, mean SD 148.4 25.2 150.1 25.3 0.048
Diastolic AP, mean SD 82.8 14.3 82.9 14.1 0.923
Laboratory data on admission, mean SD:
Hemoglobin (g/dL), mean SD 14.3 14.2 14.7 12.3 0.65
Glycemia (mg/dL), mean SD 130.5 39.8 223.5 48.2 0.362
Total cholesterol (mg/dL), mean SD 171.8 41.3 180.6 42.8 <0.001
INR, mean SD 2.2 3.3 3.5 13.6 0.152
aPresence of internal carotid/vertebral artery stenosis 50%. AF: atrial fibrillation; AP: arterial pressure; INR:
International Normalized Ratios at admission for all patients; TIA: transient ischemic attack.
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(p< 0.001), while a score between 7 and 9 was recorded
more commonly in women (12.2% and 4.4% for
women and men, respectively, p< 0.001). Men had
more severe strokes than women on NIHSS (mean
9.2 6.9 versus 8.1 7.5, respectively, p< 0.001).
Within 90 days, women had 46 (8.2%) recurrent ische-
mic events (stroke/TIA/systemic embolism) and 19
(3.4%) symptomatic cerebral bleedings compared to
30 (6.4%) and 18 (3.8%), respectively, in men
(p¼ 0.28 and p¼ 0.74). At 90 days, 57.7% women
were disabled or deceased compared to 41.1% of men
(p< 0.001) (Table 3). In multivariate analysis, this sig-
nificance was not confirmed (for unfavorable outcome
– odds ratio (OR), 0.783, 95% confidence interval (CI),
0.536–1.143, p¼ 0.205 and for mortality – OR, 1.287,
95% CI, 0.726–2.284, p¼ 0.388) (Table 4).
Regarding sex differences, East European Stroke
Units had 71 patients: 33 women (46.5%) and 38 men
(53.5%)) and other Stroke Units in Europe (900
patients: 492 women (54.7%) and 408 men (45.3%)).
Table 3. Treatment of patients in the acute period of stroke and outcome effects at 90 days.
Variables Women Men p-Value
Revascularization therapy (IV and/or IA), n (%) 115 (20.6) 96 (20.6) 1.0
HT on neuroimaginga, n (%): 79 (14.1) 55 (11.9) 0.307
hemorrhagic infarction, n (%) 55 (11.0) 37 (9.1) 0.437
parenchymal hematoma, n (%) 24 (4.9) 18 (4.4) 0.874
Therapy with anticoagulants after index stroke, n (%) 399 (71.3) 367 (78.4) 0.01
Type of anticoagulation, n (%):
LMWH 68 (12.1) 45 (9.6) 0.197
Oral anticoagulants (warfarin/DOA) 196 (35.0) 181 (38.7) 0.22
Bridging therapy (LMWH, followed by oral anticoagulants) 135 (24.1) 141 (30.1) 0.03
No anticoagulants at all 161 (28.8) 101 (21.6) 0.009
Time when anticoagulant therapy
was initiated, mean SD, days
6.5 12.4 6.4 11.7 0.902
Outcome effects, n (%):
Outcome ischemic events 46 (8.2) 30 (6.4) 0.284
Symptomatic HT 19 (3.4) 18 (3.8) 0.738
Mortality at 90 days 64 (11.6) 47 (10.1) 0.481
Unfavorable functional outcome (mRS 3-6) at 90 days 319 (57.7) 191 (41.1) <0.001
aNeuroimaging performed after 24–72 h from stroke onset. DOA: direct oral anticoagulants; HT: hemorrhagic trans-
formation (either hemorrhagic infarction or parenchymal hematoma); IA: intra-arterial revascularization therapy; IV:
intravenous revascularization therapy; LMWH: low molecular weight heparin.
Table 2. Findings on transthoracic echocardiography, performed in 843 patients.
Variables Women Men p-value
Atrial enlargement, n (%): 304 (68.5) 244 (62.7) 0.092
Mild 75 (28.3) 70 (26.8) 0.77
Moderate 113 (39.6) 90 (35.2) 0.287
Severe 116 (43.8) 81 (32.1) 0.007
Intracardiac thrombus, n (%) 4 (0.9) 7 (1.8) 0.383
Cardiomyopathy, n (%) 37 (8.31) 62 (15.9) 0.001
Mitral disease, n (%) 209 (46.8) 152 (39.0) 0.025
Aortic disease, n (%) 137 (30.6) 93 (23.9) 0.03
Tricuspid disease, n (%) 118 (26.3) 95 (24.5) 0.578
Biologic aortic prosthesis 4 (0.8) 6 (1.5) 0.526
Mechanical aortic prosthesis, n (%) 8 (1.7) 9 (2.2) 0.627
Biologic mitral prosthesis, n (%) 4 (0.8) 4 (0.7) 1.0
Mechanical mitral prosthesis, n (%) 15(3.2) 8 (2.0) 0.298
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Comparing women and men from Eastern Europe, the
former were older (mean age 79.9 8.3 versus 71.2
11.8, respectively, p< 0.001) and had more severe
strokes than men (mean NIHSS 10.0 7.2 versus
5.8 4.96, respectively, p¼ 0.006) (Supplementary
Table 1). No differences in the rates of prescribing anti-
coagulants between women and men in East Europe
before and after index stroke were observed. While,
after index stroke, LMWHs were prescribed more
often to women than men (66.7% versus 31.6%,
p¼ 0.004) and much more often than oral anticoagu-
lants in East Europe. There were no observed sex dif-
ferences regarding the time of initiating anticoagulant
therapy in East Europe: (3.95 15.9 days for men
versus 3.67 7.5 days for women, p¼ 0.923).
(Supplementary Table 2).
Discussion
This study found that women overall in Europe with
AF were less likely to receive oral anticoagulants prior
to and after stroke compared to men and regardless of
the fact that women were significantly younger and
with less severe stroke at onset; outcomes did not
differ between the sexes. The RAF-study included
more women (54.5%) than men, who were on average
younger and had less severe stroke at onset compared
to previous studies.16,17 Moreover, while previous
studies had included patients with all types of stroke
and with and without AF,16–18 the RAF-study included
only ischemic stroke patients with AF. Furthermore,
women more frequently had mitral disease and
severe atrial enlargement. The latter fact has been
reported by Go´mez-Doblas, who has stating that
women have more rheumatic aetiologies, while men
tend to be more affected by ischemic or congenital
aetiologies.19 Rheumatic aetiologies have been corre-
lated with a higher embolic risk of AF and an earlier
onset of stroke.20
In this study, women were less likely to receive oral
anticoagulants before the index stroke, a finding in
line with past population studies.8,9 Likewise, women
were less likely to receive anticoagulation therapy
for secondary prevention. This clear disparity in treat-
ment delivery has also been documented by the
Austrian Stroke Unit Registry.18 This under-treatment
for women has been hypothesized as being due to a
lack of social support, as well as other concomitant
diseases afflicting these patients, including cognitive
decline, a higher burden of vascular brain disease, epi-
lepsy and an increased risk of falls.18 Furthermore, we
also observed that women had a lower rate of statin
use, despite an equal rate of atherosclerosis between
the sexes.18,21
Table 4. Multivariate logistic regression model for dichotomous outcomes.
Variables
Unfavorable outcome Mortality
OR 95% CI p OR 95% CI P
Age 1.039 1.018–1.062 <0.001 1.044 1.009–1.079 0.014
NIHSS on admission 1.178 1.136–1.222 <0.001 1.076 1.037–1.118 <0.001
Diabetes mellitus 1.133 0.734–1.747 0.574 1.277 0.695–2.345 0.431
Previous use of antiplatelets 0.999 0.669–1.492 0.996 0.907 0.496–1.661 0.752
Previous use of oral anticoagulants 1.139 0.708–1.834 0.591 1.484 0.720–3.058 0.285
Previous use of statins 0.629 0.360–1.099 0.104 1.080 0.475–2.456 0.854
Hypertension 0.830 0.513–1.343 0.448 0.874 0.421–1.814 0.717
Hyperlipidemia 0.890 0.537–1.476 0.653 0.814 0.376–1.763 0.602
Paroxysmal AF 0.848 0.524–1.374 0.503 1.037 0.501–2.147 0.922
History of stroke/TIA 1.734 1.148–2.620 0.009 0.741 0.405–1.357 0.332
Smoking 0.939 0.673–1.308 0.709 1.318 0.833–2.086 0.238
Alcoholism 1.528 0.720–3.243 0.269 1.928 0.690–5.387 0.211
Chronic heart failure 1.235 0.767–1.989 0.385 0.962 0.501–1.845 0.907
History of myocardial infarction 1.194 0.737–1.934 0.470 1.240 0.638–2.411 0.526
Pacemaker 1.048 0.562–1.955 0.883 2.130 0.959–4.733 0.063
Small ischemic lesion 0.408 0.195–0.853 0.017 0.090 0.027–0.295 <0.001
Leukoaraiosis 0.991 0.688–1.427 0.961 1.394 0.816–2.379 0.224
Therapy with anticoagulants
after index stroke
0.389 0.249–0.605 <0.001 0.237 0.137–0.411 <0.001
AF: atrial fibrillation; AP: arterial pressure; INR: International Normalized Ratios at admission for all patients; TIA: transient ischemic attack.
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Even though men were older and had more severe
stroke, the mortality and disability rates between the
sexes were similar. The selection of patient cohorts
could have influenced this, as only cardioembolic
strokes were included, which could also explain the
younger age of women at stroke onset.
Study limitations
This hospital-based clinical study was not randomized
but based upon consecutively admitted patients fulfill-
ing inclusion criteria.
Conclusions
The RAF-study observed that women regardless of
lower NIHSS-score at admission and younger age,
experienced the same outcomes as men with higher
NIHSS at admission and older age. Moreover, this
study also observed that women were less likely, com-
pared to men, to have been prescribed anticoagulants
before and after stroke.
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